News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Venkatraman Radhakrishnan: Time to move away from Dexamethasone for prevention of chemotherapy induced nausea and vomiting
Venkatraman Radhakrishnan/stjude.org
Jan 24, 2024, 17:18

Venkatraman Radhakrishnan: Time to move away from Dexamethasone for prevention of chemotherapy induced nausea and vomiting

Venkatraman Radhakrishnan, Professor and Head of the Department of Medical Oncology at the Adyar Cancer Institute, shared on X/Twitter:

“Time to move away from Dexamethasone for prevention of chemotherapy induced nausea and vomiting (CINV).

  • Phase 3 double blind RCT.
  • DEX free prophylaxis is effective.
  • Lesser side effects like insomnia.”

Additional information.

Source: Venkatraman Radhakrishnan/X

cancer chemotherapy induced nausea and vomiting CINV dexamethasone OncoDaily Oncology RCT Venkatraman Radhakrishnan
Special Coverage
Positive
Apr 1, 2025, 15:45
Mark Lanasa: Positive CHMP opinion for BeOne Medicines' first-line immunotherapy in ES-SCLC
Blog
Apr 1, 2025, 15:09
Hagop Kantarjian: Success, optimism, and challenges on the therapeutic horizon of acute myeloid leukemia
Blog
Apr 1, 2025, 15:04
Call for Papers: AI in Immune-Related Adverse Events (irAEs) - AI in Precision Oncology
Career
Apr 1, 2025, 14:57
Sharon Burk completes PhD with groundbreaking research - Sbarro Health Research Organization
Blog
Apr 1, 2025, 14:35
Douglas Flora: The messy truth behind healthcare's coming AI adoption
Blog
Apr 1, 2025, 14:31
Zainab Shinkafi-Bagudu: Processed meats and fried snacks may increase the risk of colorectal cancer
Societies
Apr 1, 2025, 14:08
Myeloma Paper of the Day, April 1st, suggested by Robert Orlowski
Blog
Apr 1, 2025, 12:54
CTOS Communications Committee's survey to understand your engagement with social media
Science
Apr 1, 2025, 12:48
Yan Leyfman: Dual-Targeted CAR-T Therapy Shows 100% Response in MCL
Blog
Apr 1, 2025, 12:43
By 2040, the global burden of colorectal cancer is expected to rise by 63% - Digestive Cancers Europe
Blog
Apr 1, 2025, 12:34
Asya Agulnik: Breakthrough approaches needed for pediatric cancer treatment in conflict-affected regions
Blog
Apr 1, 2025, 12:18
What if 'No Response' Becomes 'No Recurrence' in Colorectal Cancer Treatment? - CancerWorld